Royalty Pharma (RPRX) to Release Quarterly Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will likely be announcing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $1.11 per share and revenue of $765.01 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The company had revenue of $578.67 million for the quarter, compared to analysts’ expectations of $750.06 million. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $36.41 on Wednesday. Royalty Pharma has a 12-month low of $24.05 and a 12-month high of $38.00. The stock has a market capitalization of $21.23 billion, a P/E ratio of 21.05, a P/E/G ratio of 2.05 and a beta of 0.60. The firm’s 50-day moving average is $36.16 and its two-hundred day moving average is $35.12. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. Royalty Pharma’s dividend payout ratio (DPR) is currently 50.87%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. raised its holdings in Royalty Pharma by 134.8% in the second quarter. Osaic Holdings Inc. now owns 7,104 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 4,078 shares during the period. Vident Advisory LLC purchased a new position in Royalty Pharma in the second quarter valued at approximately $261,000. Focus Partners Wealth purchased a new position in Royalty Pharma in the first quarter valued at approximately $264,000. EP Wealth Advisors LLC raised its holdings in Royalty Pharma by 19.6% in the second quarter. EP Wealth Advisors LLC now owns 9,314 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 1,529 shares during the period. Finally, Captrust Financial Advisors raised its holdings in Royalty Pharma by 4.4% in the second quarter. Captrust Financial Advisors now owns 12,613 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 526 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analysts Set New Price Targets

RPRX has been the topic of several research analyst reports. Morgan Stanley decreased their target price on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Wall Street Zen cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, September 13th. Citigroup raised their target price on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, July 22nd. Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday. Finally, The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Royalty Pharma currently has a consensus rating of “Buy” and a consensus target price of $46.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.